BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825 AND Staging
63 results:

  • 1. Disulfideptosis-associated lncRNAs reveal features of prognostic, immune escape, tumor mutation, and tumor malignant progression in renal clear cell carcinoma.
    Li X; Deng X; Liu T; Zhang W; Tao J
    Aging (Albany NY); 2024 Feb; 16(4):3280-3301. PubMed ID: 38334964
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Natural small-molecules reverse Xeroderma Pigmentosum Complementation Group C (XPC) deficient-mediated drug-resistance in renal cell carcinoma.
    Chen R; Lo HH; Yang C; Law BYK; Chen X; Lam CCI; Ho C; Cheong HL; Li Q; Zhong C; Ng JPL; Peter CKF; Wong VKW
    Phytomedicine; 2024 Feb; 124():155310. PubMed ID: 38215574
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update.
    Brouwer OR; Albersen M; Parnham A; Protzel C; Pettaway CA; Ayres B; Antunes-Lopes T; Barreto L; Campi R; Crook J; Fernández-Pello S; Greco I; van der Heijden MS; Johnstone PAS; Kailavasan M; Manzie K; Marcus JD; Necchi A; Oliveira P; Osborne J; Pagliaro LC; Garcia-Perdomo HA; Rumble RB; Sachdeva A; Sakalis VI; Zapala Ł; Sánchez Martínez DF; Spiess PE; Tagawa ST
    Eur Urol; 2023 Jun; 83(6):548-560. PubMed ID: 36906413
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Theranostic cobalt-55/58m for neurotensin receptor-mediated radiotherapy in vivo: A pilot study with dosimetry.
    Lin W; Aluicio-Sarduy E; Houson HA; Barnhart TE; Tekin V; Jeffery JJ; Weichmann AM; Barrett KE; Lapi SE; Engle JW
    Nucl Med Biol; 2023; 118-119():108329. PubMed ID: 36805869
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Identification of Survival Risk and Immune-Related Characteristics of kidney Renal Clear Cell Carcinoma.
    Wu X; Liang Y; Chen X; Long X; Xu W; Liu L; Wang B; Zou X
    J Immunol Res; 2022; 2022():6149369. PubMed ID: 35832648
    [TBL] [Abstract] [Full Text] [Related]  

  • 6.
    Mittlmeier LM; Todica A; Gildehaus FJ; Unterrainer M; Beyer L; Brendel M; Albert NL; Ledderose ST; Vettermann FJ; Schott M; Rodler S; Marcon J; Ilhan H; Cyran CC; Stief CG; Staehler M; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1711-1720. PubMed ID: 34708249
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Glycoforms of human prostate-specific membrane antigen (PSMA) in human cells and prostate tissue.
    Yuan W; Liu B; Sanda M; Wei R; Benicky J; Novakova Z; Barinka C; Goldman R
    Prostate; 2022 Jan; 82(1):132-144. PubMed ID: 34662441
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Comprehensive Analysis of Glutamate-Rich WD Repeat-Containing Protein 1 and Its Potential Clinical Significance for Pancancer.
    Wu Y; Wu X; Li Y; Zhao W; Yue Y; Wu B; Liu J; Chen X; Shen A
    Biomed Res Int; 2021; 2021():8201377. PubMed ID: 34616846
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A 25 year perspective on advances in the pathologic assessment and diagnosis of urologic cancers.
    Hansel DE
    Urol Oncol; 2021 Sep; 39(9):582-594. PubMed ID: 34215506
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Hydronephrosis in patients with cervical cancer is an indicator of poor outcome: A nationwide population-based retrospective cohort study.
    Yang YR; Chen SJ; Yen PY; Huang CP; Chiu LT; Lin WC; Chen HY; Chen YH; Chen WC
    Medicine (Baltimore); 2021 Feb; 100(6):e24182. PubMed ID: 33578522
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver?
    Rodler S; Apfelbeck M; Schulz GB; Ivanova T; Buchner A; Staehler M; Heinemann V; Stief C; Casuscelli J
    Eur Urol Focus; 2020 Sep; 6(5):1097-1103. PubMed ID: 32534969
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Golgi Alpha-Mannosidase II as a Novel Biomarker Predicts Prognosis in Clear Cell Renal Cell Carcinoma.
    Li C; Guo L; Chen F; Yu W; Rao T; Ruan Y
    Oncol Res Treat; 2020; 43(6):264-275. PubMed ID: 32403105
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. 64CuCl2 PET/CT as a potential new imaging method in prostate cancer: illusion or reality?
    Cantiello F; Crocerossa F; Cascini GL; Russo GI; Ferro M; Cimino S; Lucarelli G; Damiano R
    Minerva Urol Nephrol; 2021 Oct; 73(5):668-671. PubMed ID: 32182228
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.
    Vornov JJ; Peters D; Nedelcovych M; Hollinger K; Rais R; Slusher BS
    Neurochem Res; 2020 Jun; 45(6):1256-1267. PubMed ID: 31749072
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Evaluation of a Neurokinin-1 Receptor-Targeted Technetium-99m Conjugate for Neuroendocrine Cancer Imaging.
    Kanduluru AK; Srinivasarao M; Wayua C; Low PS
    Mol Imaging Biol; 2020 Apr; 22(2):377-383. PubMed ID: 31292915
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Value of Ferritin Heavy Chain (FTH1) Expression in Diagnosis and Prognosis of Renal Cell Carcinoma.
    Huang H; Qiu Y; Huang G; Zhou X; Zhou X; Luo W
    Med Sci Monit; 2019 May; 25():3700-3715. PubMed ID: 31104064
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma.
    Smith CC; Beckermann KE; Bortone DS; De Cubas AA; Bixby LM; Lee SJ; Panda A; Ganesan S; Bhanot G; Wallen EM; Milowsky MI; Kim WY; Rathmell WK; Swanstrom R; Parker JS; Serody JS; Selitsky SR; Vincent BG
    J Clin Invest; 2018 Nov; 128(11):4804-4820. PubMed ID: 30137025
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Acetyl-CoA synthetase 2 enhances tumorigenesis and is indicative of a poor prognosis for patients with renal cell carcinoma.
    Zhang S; He J; Jia Z; Yan Z; Yang J
    Urol Oncol; 2018 May; 36(5):243.e9-243.e20. PubMed ID: 29503142
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis.
    Lei Z; Ma X; Li H; Zhang Y; Gao Y; Fan Y; Li X; Chen L; Xie Y; Chen J; Wu S; Tang L; Zhang X
    Urol Oncol; 2018 Mar; 36(3):93.e23-93.e37. PubMed ID: 29066014
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The role of
    Ma Z; Qi Z; Shan Z; Li J; Yang J; Xu Z
    Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 28923830
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.